Medicinal chemistry & drug design

Albert Antolín Hernández

POSTDOCTORAL RESEARCHERS
  • Leticia Manen Freixa
PREDOCTORAL RESEARCHERS
  • Luca Ruvo
SCIENTIFIC SUPPORT
  • Santiago Santos Gil
Cancer
Oncobell

Scientific production

6

PAPERS

Average IF: 8,48

2

LED PAPER

Average IF: 6,3

1 PUBLICATION IN FIRST DECILE

4 PUBLICATIONS IN FIRST QUARTILE

5 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Sanfelice,D;Antolin,AA;Crisp,A;Chen,Y;Bellenie,B;Brennan,PE;Edwards,A et al, The Chemical Probes Portal-2024: update on this public resource to support best-practice selection and use of small molecules in biomedical research, Nucleic Acids Res., 2024;53(D1):1663-1669, doi:10.1093/nar/gkae1062
  • Bellot,M;Manen,L;Prats,E;Bedrossiantz,J;Barata,C;Gómez Canela,C;Antolin,AA et al, Short-term exposure to environmental levels of nicotine and cotinine impairs visual motor response in zebrafish larvae through a similar mode of action: Exploring the potential role of zebrafish a7 nAChR, Sci Total Environ, 2024;912169301-169301, doi:10.1016/j.scitotenv.2023.169301
  • Walpole,IR;Zaman,FY;Zhao,PA;Marshall,VM;Lin,FP;Thomas,DM;Shackleton,M et al, Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases, Clin Transl Med, 2024;14(4):doi:10.1002/ctm2.1657
  • Hu,HB;Serra,C;Zhang,WJ;Scrivo,A;Fernández Carasa,I;Consiglio,A;Aytes,A et al, Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite, Cell Chem Biol, 2024;31(5):doi:10.1016/j.chembiol.2024.01.007
  • Manen Freixa,L;Antolin,AA, Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery, Expert. Opin. Drug Discov., 2024;19(9):1-27, doi:10.1080/17460441.2024.2376643

Research highlights

PROJECTS

3 Ongoing competitive projects

1 Ongoing competitive project

NETWORKS

Chemical Probes Portal
canSAR
Target 2035
MAINFRAME

Selected projects

  • CP22/00122. CONTRATOS MIGUEL SERVET. Instituto de Salud Carlos III (ISCIII). Budget: 202.500€. 2023-2028. PI: ANTOLIN HERNANDEZ, ALBERT.
  • PID2022-136344OA-I00. Caracterización de metabolitos de farmacos usando biologia de sistemas para su explotación en medicina de precisión (META-PRIME). Ministerio de Ciencia e Innovación. Budget: 162.500€. 2023-2026. PI: ANTOLIN HERNANDEZ, ALBERT.
  • PNJ23029. Multi-Target Molecules for Precision Oncology in colorectal. VIVAN Therapeutics. Budget: 50.000€. 2023-2025. PI: ANTOLIN HERNANDEZ, ALBERT.
  • CP22/00122. CONTRATOS MIGUEL SERVET I – Projecte creat per al pressupost del projecte de la beneficària. Instituto de Salud Carlos III (ISCIII). Budget: 40.000€. 2023-2028. PI: ANTOLIN HERNANDEZ, ALBERT.